The article you requested is
The Effectiveness of St. John’s Wort in Major Depressive Disorder: A Naturalistic Phase 2 Follow-Up in Which Nonresponders Were Provided Alternate Medication
Alan J. Gelenberg, MD; Richard C. Shelton, MD; Paul Crits-Christoph, PhD; Martin B. Keller, MD; David L. Dunner, MD; Robert M. A. Hirschfeld, MD; Michael E. Thase, MD; James M. Russell, MD; R. Bruce Lydiard, PhD, MD; Robert J. Gallop, PhD; Linda Todd, BA; David J. Hellerstein, MD; Paul J. Goodnick, MD; Gabor I. Keitner, MD; Stephen M. Stahl, MD, PhD; Uriel Halbreich, MD; and Heather S. Hopkins, MA
J Clin Psychiatry 2004;65(8):1114-1119
© Copyright 2017 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
-
-
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
-
Subscribe
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
-
-
Activate
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
-
Sign in
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
-
Click here to login.
-
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Article Abstract
Background: A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo.
Method: Seventeen subjects with DSM-IV-defined major depressive disorder who responded to St. John's wort extract in the acute-phase study (phase 1) were continued on double-blind treatment with the same preparation for 24 weeks. Ninety-five subjects who did not respond to either St. John's wort or placebo were treated with an antidepressant for 24 weeks.
Results: During antidepressant treatment, mean scores on the Hamilton Rating Scale for Depression for phase 1 nonresponders decreased significantly (p < .0001), with no significant difference between St. John's wort nonresponders and placebo nonresponders. Of the 17 subjects continued on treatment with St. John's wort extract, 5 (29.4%) relapsed.
Conclusions: The subjects who did not respond to St. John's wort extract or placebo in phase 1 were, by and large, not resistant to antidepressant treatment. This suggests that the lack of efficacy found by Shelton et al. in the acute-phase study was unlikely to be the result of a high proportion of treatment-resistant subjects.